Byetta and Januvia Pancreatic Cancer Lawsuits should be Consolidated in Federal Court
Diabetes drugs Byetta and Januvia are causing an increase in pancreatic cancer among patients. As a result, multiple victims are filing lawsuits after suffering adverse effects from Byetta and Januvia across the country. The fact that so many lawsuits have been filed has prompted attorneys to ask that Byetta and Januvia pancreatic cancer lawsuits be […]
FDA Evaluating Link Between Byetta and Pancreatic Cancer
In March of this year, the Food and Drug Administration released the following safety alert: “Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication – Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas.” The FDA reports that it is evaluating academic research that links these drugs with the elevated risk […]
Byetta May Increase Risk of Pancreatic Cancer
A recent study by the Larry L. Hillblom Islet Research Center at the University of California in Los Angeles has found that persons with type 2 diabetes who take Byetta (also known as exenatide) to control their blood-sugar levels may be at greater risk of developing pancreatic cancer. The study uncovered evidence of precancerous changes […]
Advice For Dealing With Your Diagnosis, From an Actos Bladder Cancer Victim Lawyer
If you were diagnosed with bladder cancer while using the diabetes drug Actos, your losses extend far beyond the medical costs, pain and lost time during your treatment and recovery. Since bladder cancer has a high rate of recurrence, you will be dealing with this for years to come as you endure follow-up tests and […]
The Levensten Law Firm Represents Many Injured Victims of Metallic Hip Implant Lawsuits
Metallic hip implants are implants in which both the ball, and socket components of an artificial hip are metal. Studies show that these implants are failing at a high rate due to premature wear. Full metal implants often need to be replaced within the first few years of use, while hip replacements containing a combination […]
Time is Running Out – Protect Your Rights To Bring Your Claims For Injuries From Your Pelvic Mesh Implant
Many women experience pelvic organ prolapse, or collapse of the pelvic floor, following child birth, having a hysterectomy or menopause. With this condition, pelvic organs slip out of place, or even protrude from the body. Since the 1990’s, transvaginal mesh devices have been used as a treatment for pelvic organ prolapse in women and were […]
Takeda Facing Trial Over Actos in California As Evidence Emerges That Exec's Hid Risks in 2003 To Protect Sales
In 1999 the FDA approved a drug developed by Takeda Pharmaceuticals for the treatment of Type 2 diabetes. Actos, from the class of drugs known as thiazolidinediones is said to increase the sensitivity to insulin. Fourteen years later, the affects of this drug are presenting themselves. In 2010, the FDA came out with a safety […]
Takeda Facing Trial Over Actos in California As Evidence Emerges That Exec’s Hid Risks in 2003 To Protect Sales
In 1999 the FDA approved a drug developed by Takeda Pharmaceuticals for the treatment of Type 2 diabetes. Actos, from the class of drugs known as thiazolidinediones is said to increase the sensitivity to insulin. Fourteen years later, the affects of this drug are presenting themselves. In 2010, the FDA came out with a safety […]
First Vaginal Mesh Trials Proceeding
The first vaginal mesh recall goes back to the 1990s when Boston Scientific Corp. voluntarily took its ProteGen device off the market. Since then, Mentor Worldwide stopped production of its ObTape product in 2006 and just last year Johnson & Johnson took four of their mesh products off the market. How has the Federal Drug […]
MDL PLAINTIFF EXECUTIVE COMMITTEE RESPONSE TO DEPUY SETTLEMENT REPORTS IN THE PRESS
In response to Bloomberg Reports about a potential DePuy Settlement, the Plaintiff’s Executive Committed issued the following statement: “Today, it was reported that five people close to the DePuy ASR MDL 2197 litigation confirmed settlement discussions. You should know that last night the leadership of the Executive Committee, emailed the following statement to the reporters: […]
